|Systematic (IUPAC) name|
|Oral, Insufflation, Rectal|
7px (racemic) |
|357 mg/mL (20 °C)|
|14px (what is this?)|
Methylone, also known as M1, 3,4-methylenedioxy-N-methylcathinone, MDMC, bk-MDMA is an entactogen and central nervous system (CNS) stimulant of the phenethylamine, amphetamine, cathinone and methylenedioxyphenethylamine classes. It was first synthesized by chemists Peyton Jacob III and Alexander Shulgin in 1996 for potential use as an antidepressant. Methylone is a close structural analog of MDMA, differing by the addition of a β-ketone group.
At the end of 2004, a new designer drug called "Explosion" appeared in the Netherlands. This drug was sold as a liquid via the internet and in Dutch "smartshops". The stores were selling chemicals that, at the time, were non-scheduled, but which usually became illegal within a year of becoming well-known. These included psychoactive substances such as Salvia divinorum, Psilocybin mushrooms and other MDMA substitutes like BZP and TFMPP. The product was advertised as a "room odorizer" and was sold in plastic tubes containing 5 mL of liquid. The tubes cost between €10 and €15 ($13–$20) and did not present any information about the ingredients of Explosion; they had only a label that read, "Room odorizer Vanilla. Do not ingest" and "Keep away from children. Never use more than one bottle". Users have mentioned ingesting the liquid to reach euphoric stimulating effects similar to those of MDMA. The label circumvented Dutch regulations for illicit drugs and psychoactive substances when intentionally used for intoxication. Analysis of "Explosion" has confirmed that the active ingredient is methylone.[unreliable source?] Many other formulations marketed as household chemicals, as well as the pure powder, have been sold.
Reported dosages range from 100 to 250 mg orally. Some respondents say that increasing dose with methylone beyond 100–180 mg causes increased physical effects and does not substantially improve the empathic cognitive effects.
The effects of methylone may include the following:[medical citation needed]
- Euphoria or dysphoria, and anxiolysis or anxiogenesis, depending on the individual.
- An increase in sociability.
- Insomnia and restlessness
- Derealization/depersonalization, hallucinations, and psychosis, depending on the individual, and in all individuals with high dosage or extended use.
- Tachycardia and hypertension
- Hyperthermia and sweating
- Mydriasis and nystagmus
- Trismus and bruxism
- Nausea and vomiting
- short term erectile dysfunction
Most of these effects are very similar to those of other psychostimulants.
Resemblance to MDMA
Methylone substitutes for MDMA in rats trained to discriminate MDMA from saline. Methylone does not substitute for amphetamine or for the hallucinogenic DOM in animals trained to discriminate between these drugs and saline. Further, also in common with MDMA, methylone acts on monoaminergic systems. In vitro, methylone has one third the potency of MDMA at inhibiting platelet serotonin accumulation and about the same in its inhibiting effects on the dopamine and noradrenaline transporters.
In spite of these behavioral and pharmacological similarities between methylone and MDMA, the observed subjective effects of both drugs are not completely identical. Alexander Shulgin wrote of the former:
"[Methylone] has almost the same potency of MDMA, but it does not produce the same effects. It has an almost antidepressant action, pleasant and positive, but not the unique magic of MDMA."
Methylone acts as a mixed reuptake inhibitor/releasing agent of serotonin, norepinephrine, and dopamine. In comparison to MDMA, it has approximately 3x lower affinity for the serotonin transporter, while its affinity for the norepinephrine and dopamine transporters is similar. Notably, methylone's affinity for the vesicular monoamine transporter 2 (VMAT2) is about 13x lower than that of MDMA. The results of these differences in pharmacology relative to MDMA are that methylone is less potent in terms of dose, has more balanced catecholaminergic effects relative to serotonergic, and behaves more like a reuptake inhibitor like methylphenidate than a releaser like amphetamine; however, methylone has relatively robust releasing capabilities, perhaps due to its ability to phosphorylate the monoamine transporters being similar in potency relative to MDMA.
The two major metabolic pathways in mammals for methylone are N-demethylation to methylenedioxycathinone (MDC), and demethylation followed by O-methylation of the 3- or 4-hydroxy group to 4-hydroxy-3-methoxymethcathinone (HMMC) or 3-hydroxy-4-methoxymethcathinone (3-OH-4-MeO-MC). When 5 mg/kg of methylone was administered to rats, it was found that around 26% was excreted as HMMC within the first 48 hours (less than 3% excreted unchanged).
In the Netherlands, methylone is not yet listed under the Opium Law, but is covered under the medicine act. Because methylone is not registered officially, as such, it is forbidden to trade in methylone. The Minister of Health has asked the Coordination point Assessment and Monitoring new drugs group (CAM) to gather information about this substance, resulting possibly in an official risk assessment. Until now, no research has been conducted on the toxicity of methylone, so nothing is known about the harmfulness of this new drug.
In New Zealand, although methylone is not explicitly scheduled and falls outside the strict definitions of an "amphetamine analogue" in the Misuse of Drugs Act, it is considered to be "substantially similar" to methcathinone and is thus considered by law enforcement authorities to be a Class C illegal drug. Methylone was sold in New Zealand for around 6 months from November 2005 to April 2006 as an MDMA substitute, under the name "Ease". The product was withdrawn after legal disputes with the government.
In the UK, methylone is illegal since the 16/04/2010 revision of the misuse of drugs act. Before this it was not specifically mentioned in United Kingdom (U.K.) law as the β-ketone was not covered under the Misuse of Drugs Act. In March 2010, plans were announced to make methylone and other cathinones, Class B drugs, "within weeks". While delayed by dissatisfaction in the ACMD, the revision was rushed through by the government with little regard for the views of the ACMD. The importation of the compounds was banned immediately.
Sveriges riksdag added methylone to schedule I ("substances, plant materials and fungi which normally do not have medical use") as narcotics in Sweden as of Oct 1, 2010, published by Medical Products Agency in their regulation LVFS 2010:23 listed as Metylon, 2-metylamino-1-(3,4-metylendioxifenyl)propan-1-on. Methylone was first classified by Sveriges riksdags health ministry Statens folkhälsoinstitut as "health hazard" under the act Lagen om förbud mot vissa hälsofarliga varor (translated Act on the Prohibition of Certain Goods Dangerous to Health) as of Nov 1, 2005, in their regulation SFS 2005:733 listed as 3,4-metylendioximetkatinon (Metylon).
Although not listed as a Schedule 1  substance, Health Canada reports that methylone falls under the scheduling as an analogue of amphetamine. However, Methylone bears the exact chemical difference between amphetamine and cathinone - and cathinone is listed as not being an analogue of amphetamine. Leading to imply that methylone is unscheduled in Canada. The CDSA was updated as a result of the Safe Streets Act changing amphetamines from Schedule 3 to Schedule 1; however, methylone was not added.
- Effective February 16, 2012, methylenedioxymethcathinone (methylone) was classified as a dangerous drug, making it a felony to knowingly possess, use, possess for sale, manufacture, administer, transport for sale, import into the state, or offer to transport for sale or import into this state, sell, transfer or offer to sell or transfer. A.R.S. 13-3401(6)(c)(xliii), 2012 Ariz. Legis. Serv. Ch. 1 (H.B. 2356).
- In January 2011, it was reported that Florida Attorney General Pam Bondi issued an emergency ban on MDPV, Methylone, Mephedrone, 3-methoxymethcathinon, 3-fluoromethcathinone, and 4-fluoromethcathinone as media attention on products labeled as "bath salts" grew. These chemicals are now Schedule I under Florida law.
- On May 5, 2011, Tennessee Governor Bill Haslam signed a law making it a crime to knowingly produce, manufacture, distribute, sell, offer for sale or possess with intent produce, manufacture, distribute, sell, or offer for sale any product containing 3,4-methylenedioxymethcathinone (methylone), 3,4-methyenedioxypyrovalerone (MDPV), 4-methylmethcathinone (mephedrone), 4-methoxymethcathinone (methedrone), 4-fluoromethcathinone (flephedrone), and 3-fluoromethcathinone (3-FMC).
- In September 2011, Texas added 3,4-methylenedioxy-N-methylcathinone to the Penalty Group 2 listing of the Health and Safety Code. Possession of a substance in penalty group 2 is a minimum of a state jail felony.
- Schedule 1 controlled substance in 2012. As of 4/12/2013 the DEA placed Methylone as a Schedule 1 substance under the CSA.
"Methylone" is also a trademarked brand name for an injectable form of methylprednisolone, a corticosteroid hormone used to treat arthritis and severe allergic reactions; hence, methylone may be confused with it. Aside from context, they can be distinguished by the fact that the name will usually be capitalized when referring to the prescription drug.
A proposed alternate name is bk-MDMA, or beta-keto-MDMA. While this nomenclature has not caught on because the name "methylone" became widely used before the conflicting Methylone trademark was noticed, the analogous names for related chemicals bk-MDEA and bk-MBDB have become the established names for those substances.
- "Ustawa z dnia 15 kwietnia 2011 r. o zmianie ustawy o przeciwdziałaniu narkomanii ( Dz.U. 2011 nr 105 poz. 614 )". Internetowy System Aktów Prawnych. Retrieved 17 June 2011.
- WO 9639133
- Cozzi NV, Sievert MK, Shulgin AT, Jacob P, Ruoho AE (September 1999). "Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines". European Journal of Pharmacology 381 (1): 63–9. PMID 10528135. doi:10.1016/S0014-2999(99)00538-5.
- "Methylone sold under "Explosion" and "Inpact" brand names in the Netherlands and Japan," by Uil & Erowid, v1.2 - Apr 2005, www.erowid.org
- TA Dal Cason, R Young, RA Glennon. Cathinone: an investigation of several N-alkyl and methylenedioxy-substituted analogs. Pharmacol. Biochem. Behav. 58, 1109–1116 (1997)
- NV Cozzi, MK Sievert, AT Shulgin, P Jacob III, AE Ruoho. Methcathinone and 2 methylamino-1-(3,4-methylenedioxyphenyl)propan-1-one (methylone) selectively inhibit plasma membrane catecholamine reuptake transporters. Soc. Neurosci. Abs., 24, 341.8 (1998).
- NV Cozzi, AT Shulgin, AE Ruoho. Methcathinone (MCAT) and 2-methylamino-1-(3,4 methylenedioxyphenyl)propan-1-one (MDMCAT) inhibit [3H]serotonin uptake into human platelets. Amer. Chem. Soc. Div. Med. Chem. Abs., 215, 152 (1998).
- "Cathinone | Ask Dr. Shulgin Online".
- Nagai F, Nonaka R, Satoh Hisashi Kamimura K (March 2007). "The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain". European Journal of Pharmacology 559 (2–3): 132–7. PMID 17223101. doi:10.1016/j.ejphar.2006.11.075.
- Xenobioica. HT Kamata, N Shima, K Zaitsu, T Kamata, A Miki, M Nishikawa, M Katagi, H Tsuchihashi. (2006). Metabolism of methylone in humans and rats. Volume 36, Number 8 / August 2006.
- van Amsterdam et al., 2004
- "Party pill sparks official concern". One News. 7 April 2006. Retrieved 23 October 2011.
- "EASE trial terminated after conflicting advice," scoop.co.nz (April 9, 2006).
- "Suspected mephedrone-type compound seized at airport". BBC News. 1 April 2010. Retrieved 3 April 2010.
- "Chemicals Used in 'Bath Salts' Now Under Federal Control and Regulation". USA Dept of Justice. Retrieved 22 April 2014.
- "Schedules of Controlled Substances: Placement of Methylone Into Schedule I". Retrieved 22 April 2014.
- "Schedules of Controlled Substances: Placement of Methylone Into Schedule I". 2014-04-12. Retrieved 22 April 2014.